Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
ASPEN-05
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- NCT04755244 ↗
- Terminated
- ALX Oncology Inc.
- Focused
We haven't built an HCP commentary report on ASPEN-05 (evorpacept plus venetoclax plus azacitidine in adult acute myeloid leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASPEN-05 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) (ASPEN-05)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Acute Myeloid Leukemia; AML, Adult
- Interventions
- evorpacept; venetoclax; azacitidine
- Arms
- evorpacept (ALX148) + venetoclax + azacitidine · Experimental
- Enrollment
- 14
- Primary outcomes
- Phase 1: Dose Limiting Toxicities (DLT)
- Phase 2: Composite complete remission rate (CRc)
- Sponsor
- ALX Oncology Inc.
- Start
- May 5, 2021
- Primary completion
- May 5, 2023
- Results posted
- No
- Registry record
- NCT04755244 · updated Nov 27, 2024
Publications
linked from the registry- Marks JA, Wang X, Fenu EM, Bagg A, Lai C. TP53 in AML and MDS: The new (old) kid on the block. Blood Rev. 2023 Jul;60:101055. doi: 10.1016/j.blre.2023.101055. Epub 2023 Feb 14. PubMed 36841672